

### **REMARKS**

Claims 1-16 are pending in the present application. Claims 1-5, 7, 10-12 and 14 are allowed. Claims 6, 8, 9, 13, 15 and 16 stand rejected. The Applicants cancel claims 6, 8, 9, 13, 15 and 16 without prejudice or disclaimer. No new matter is added.

### **Specification**

The specification is objected to for the use of trademarks. The Applicants amend the specification herein at pages, 2, 5, and 13 to designate sepharose and Macro-prep as trademark names as well as capitalize these names. The Applicants respectfully submit that these trademarked column resins are already described in the text of the application. For instance, MACRO-PREP® ceramic hydroxyapatite, Type I is described as a ceramic hydroxyapatite column, while SP-Sepharose, CM-Sepharose Fast Flow are described as cation exchangers and Q-Sepharose Fast Flow and Macro-Prep DEAE are described as anion exchangers. The Applicants respectfully submit that as amended the specification in condition for allowance.

### **Abstract**

The Examiner alleges that the current abstract does not adequately describe the claimed invention. The Applicants provide herein on a separate sheet a new abstract.

### **35 U.S.C. §112, second paragraph**

Claims 6, 8, 13, and 15 stand rejected under 35 U.S.C. § 112, second paragraph as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which the applicants regard as the invention. The Applicants cancel claims 6, 8, 13, and 15 herein without prejudice or disclaimer, thus, rendering rejection of these claims moot.

### **35 U.S.C. §102(b)**

Claims 9 and 16 stand rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by WO 01/00244, WO 01/24763, Liu, *et al.*, *PNAS USA* (1996) 93:8618-8623,

Liu, *et al.*, *Exp. Opin. Invest. Drugs*, (1997) 6(2):169-172, Smith, *et al.*, *Mole. Ther.* (2001) 3(2):198-203, and Rose, *et al.*, *Molec Ther.* (2001) 3(2): 198-203. The Applicants cancel claims 9 and 16 herein without prejudice or disclaimer, thus rendering rejection of these claims moot.

The Applicants reserve the right to prosecute, in one or more patent applications, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification. The Applicants thank the Examiner for the Office Action and believe this response to be a full and complete response to such Office Action. Accordingly, favorable consideration and allowance of the pending claims is earnestly solicited. If it would expedite the prosecution of this application, the Examiner is invited to confer with the Applicant's undersigned attorney.

Respectfully Submitted,

\AndreaVLockenour\

Andrea V. Lockenour  
Attorney for Applicants  
Registration No. 51,962

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-7568  
Facsimile (610) 270-5090  
n:\av1\patapps\ansamytosin and maytansinoid\p51318\roa.doc